{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:53:10Z","timestamp":1793134390255,"version":"4.5.0"},"reference-count":65,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"CECAV","award":["UID\/00772\/2025"],"award-info":[{"award-number":["UID\/00772\/2025"]}]},{"name":"FMV-ULus\u00f3fona","award":["Antivirals\/SUBgrFeLV (2022-2023)"],"award-info":[{"award-number":["Antivirals\/SUBgrFeLV (2022-2023)"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Feline leukaemia virus (FeLV) infection \u2013 particularly the progressive course \u2013 continues to cause substantial morbidity and reduced survival in cats. Therapeutic options with proven antiviral effectiveness remain limited. This study aimed to evaluate the clinical and virological effects of the integrase inhibitor raltegravir in naturally infected, FeLV-progressive cats with FeLV-related conditions, clinical outcome, viraemia, proviral burden and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 14 client-owned cats with confirmed progressive FeLV infection and at least one FeLV-related condition were enrolled. Raltegravir was administered for 90 days, followed by a 90-day treatment-free observation period. Clinical evaluation and quantification of viral RNA and proviral DNA loads were performed at treatment initiation, day 45, day 90 and day 180. Cats continued to receive standard of care as clinically indicated. Survival data were recorded until study closure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 45 days of treatment, plasma viral RNA load showed a non-significant mean reduction of 1.34 log\n                      <jats:sub>10<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.204). At day 90, mean viral load continued to decrease, with reductions of 1.10 log\n                      <jats:sub>10<\/jats:sub>\n                      at 40\u2009mg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.208) and 1.39 log\n                      <jats:sub>10<\/jats:sub>\n                      at 80\u2009mg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.195), none of which reached statistical significance. Raltegravir did not exert a consistent effect on proviral DNA load. Most FeLV-related conditions remained clinically stable or improved during the 180-day monitoring period. Leukaemia and lymphoma were the main causes of death. Median survival time was 48 months from FeLV diagnosis and 10.8 months from treatment initiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>To the authors\u2019 knowledge, this is the first prospective longitudinal study in naturally infected, FeLV-progressive cats with FeLV-related conditions assessing the effects of raltegravir on viraemia, proviral load and clinical outcomes. These real-world data suggest that raltegravir may be associated with numerical reductions in viraemia and clinical stabilisation in some cats. A definitive virological or survival benefit, however, could not be demonstrated. Longer term controlled studies \u2013 potentially within multimodal antiviral strategies \u2013 are warranted to further define its therapeutic role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x261452556","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:25:57Z","timestamp":1778732757000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and virological effects of the integrase inhibitor raltegravir in cats with naturally progressive feline leukaemia virus infection"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-524X","authenticated-orcid":false,"given":"Pedro","family":"Morais de Almeida","sequence":"first","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"Animal and Veterinary Research Center (CECAV), University of Tr\u00e1s-os-Montes and Alto Douro, Vila Real, Portugal"},{"name":"Polytechnic Institute of Lusofonia (IPLUSO), School of Health, Protection and Animal Welfare, Lisbon, Portugal"},{"name":"I-MVET- Research in Veterinary Medicine, Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6839","authenticated-orcid":false,"given":"Adriana","family":"Belas","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"Polytechnic Institute of Lusofonia (IPLUSO), School of Health, Protection and Animal Welfare, Lisbon, Portugal"},{"name":"I-MVET- Research in Veterinary Medicine, Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"Animal and Veterinary Research Center (CECAV), Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-4588","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Martins","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"Polytechnic Institute of Lusofonia (IPLUSO), School of Health, Protection and Animal Welfare, Lisbon, Portugal"},{"name":"I-MVET- Research in Veterinary Medicine, Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5977-2626","authenticated-orcid":false,"given":"Rita","family":"Picado","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Meneses","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"I-MVET- Research in Veterinary Medicine, Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"Animal and Veterinary Research Center (CECAV), Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-4199","authenticated-orcid":false,"given":"Joana","family":"Tavares de Oliveira","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"},{"name":"I-MVET- Research in Veterinary Medicine, Faculty of Veterinary Medicine, Lus\u00f3fona University-Lisbon University Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Viegas","sequence":"additional","affiliation":[{"name":"Animal and Veterinary Research Center (CECAV), University of Tr\u00e1s-os-Montes and Alto Douro, Vila Real, Portugal"},{"name":"Department of Veterinary Sciences, School of Agricultural and Veterinary Sciences (ECAV), University of Tr\u00e1s-os-Montes and Alto Douro, Vila Real, Portugal"},{"name":"CIVG-Vasco da Gama Research Center, University School Vasco da Gama, Lordem\u00e3o, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/v11110993"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2019.05.013"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0339-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2020.05.006"},{"key":"e_1_3_3_6_2","article-title":"Prevalence and risk factors of feline immunodeficiency virus and feline leukemia virus infection in healthy cats in Thailand.","volume":"9","author":"Moreno M\u00c1","year":"2022","unstructured":"Moreno M\u00c1, Mandoki M, Decaro N, et al. Prevalence and risk factors of feline immunodeficiency virus and feline leukemia virus infection in healthy cats in Thailand. Front Vet Sci 2022; 9. DOI: 10.3389\/fvets.2021.764217.","journal-title":"Front Vet Sci"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.14202\/vetworld.2022.1601-1609"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.251.2.187"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322691"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2014.12.025"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X251379219"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.146.15.419"},{"key":"e_1_3_3_13_2","volume-title":"Proceedings of the 8th International Feline Retrovirus Research Symposium","author":"Levy J","year":"2006","unstructured":"Levy J, Lorentzen L, Shields J, et al. Long-term outcome of cats with natural FeLV and FIV infection. Proceedings of the 8th International Feline Retrovirus Research Symposium; 8\u201311 October 2006; Washington, DC, USA."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13020302"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X20941785"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13030428"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01585-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X19895940"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00649-18"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/v4112684"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X12473468"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/ani10091464"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/v11090845"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2011.06.008"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2012.09.025"},{"key":"e_1_3_3_26_2","first-page":"105","article-title":"Evaluation of the expression of immune mediators in cats infected with feline leukemia virus (FeLV) treated with recombinant feline omega interferon (rFeIFN-).","volume":"109","author":"Sirage S","year":"2014","unstructured":"Sirage S, Gil S, Leal R, et al. Evaluation of the expression of immune mediators in cats infected with feline leukemia virus (FeLV) treated with recombinant feline omega interferon (rFeIFN-). Rev Port de Cienc Vet 2014; 109: 105\u2013111.","journal-title":"Rev Port de Cienc Vet"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","unstructured":"Hartmann K Sykes JE Papich MG. Antiviral chemotherapy and immunomodulatory drugs. In: Sykes JE (ed). Greene\u2019s infectious diseases of the dog and cat. 5th ed. Elsevier 2022 pp 83\u2013102.","DOI":"10.1016\/B978-0-323-50934-3.00009-4"},{"key":"e_1_3_3_28_2","first-page":"125","article-title":"In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain.","volume":"16","author":"Broll E","year":"2011","unstructured":"Broll E, Rietz C, Schulz G, et al. In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain. Antivir Ther 2011; 16: 125\u2013134.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_29_2","first-page":"502","article-title":"Efficacy of siRNA on feline leukemia virus replication in vitro.","volume":"60","author":"Lehmann M","year":"2015","unstructured":"Lehmann M, Weber K, Rauch G, et al. Efficacy of siRNA on feline leukemia virus replication in vitro. Kleintierpraxis 2015; 60: 502\u2013509.","journal-title":"Kleintierpraxis"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13081636"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1590690"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000890"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1684\/vir.2023.1021"},{"key":"e_1_3_3_34_2","unstructured":"Hartmann K Hofmann-Lehmann R. Feline leukaemia virus infection \u2013 ABCD recommendations and review of the literature. https:\/\/www.abcdcatsvets.org\/wp-content\/uploads\/2023\/01\/ABCD-FeLV-Guideline-2021.pdf (2021 accessed 19 August 2024)."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/avj.13470"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X15610676"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S17731"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2427(92)90129-E"},{"key":"e_1_3_3_39_2","first-page":"16","article-title":"AZT in the treatment of feline immunodeficiency virus infection: part 1.","volume":"23","author":"Hartmann K","year":"1995","unstructured":"Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection: part 1. Feline Pract 1995; 23: 16\u201321.","journal-title":"Feline Pract"},{"key":"e_1_3_3_40_2","first-page":"13","article-title":"AZT in the treatment of feline immunodeficiency virus infection: part 2.","volume":"23","author":"Hartmann K","year":"1995","unstructured":"Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection: part 2. Feline Pract 1995; 23: 13\u201320.","journal-title":"Feline Pract"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2011.03.039"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.039909-0"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200006000-00009"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0018046"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2014.10.031"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.29374\/2527-2179.bjvm003522"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/avj.13363"},{"key":"e_1_3_3_48_2","first-page":"652","article-title":"Multimodal therapy of a cat with FeLV infection and lymphoma.","volume":"63","author":"Lahnstein K","year":"2018","unstructured":"Lahnstein K, Pippig J, Pack A, et al. Multimodal therapy of a cat with FeLV infection and lymphoma. Kleintierpraxis 2018; 63: 652\u2013659.","journal-title":"Kleintierpraxis"},{"key":"e_1_3_3_49_2","first-page":"411","article-title":"Efficacy of COP-based protocol used with raltegravir in treatment of cats with mediastinal lymphoma and progressive viral leukemia.","volume":"18","author":"Zenchenkova AP","year":"2023","unstructured":"Zenchenkova AP, Vatnikov YA. Efficacy of COP-based protocol used with raltegravir in treatment of cats with mediastinal lymphoma and progressive viral leukemia. RUDN J Agron Anim Ind 2023; 18: 411\u2013417.","journal-title":"RUDN J Agron Anim Ind"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-025-10942-2"},{"key":"e_1_3_3_51_2","volume-title":"Proceedings of the 21st FECAVA EuroCongress","author":"de Almeida PM","unstructured":"de Almeida PM, Pedroso L. Assessing the antiviral effect of the integrase inhibitor, raltegravir in 3 cats naturally infected with feline leukemia virus [abstract]. Proceedings of the 21st FECAVA EuroCongress; 15\u201317 September 2015; Barcelona, Spain."},{"key":"e_1_3_3_52_2","article-title":"ICTV virus taxonomy profile: retroviridae 2021.","volume":"102","author":"Coffin J","year":"2021","unstructured":"Coffin J, Blomberg J, Fan H, et al. ICTV virus taxonomy profile: retroviridae 2021. J Genl Virol 2021; 102. DOI: 10.1099\/JGV.0.001712.","journal-title":"J Genl Virol"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0303.x"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266621"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.CIMID.2023.101963"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2013.11.007"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X21993657"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/2055116916646388"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15081718"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-025-04691-2"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-625"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834b9658"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-21"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2010.02.014"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.CIMID.2024.102228"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871526517666170505122800"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261452556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X261452556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261452556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:46:58Z","timestamp":1784238418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X261452556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/1098612X261452556"],"URL":"https:\/\/doi.org\/10.1177\/1098612x261452556","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1098612X261452556"}}